Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Primary Chronic Insomnia Disorder

NCT06680505 is registered in ClinicalTrials.gov with Shanghai Haiyan Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06680505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06680505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Primary Chronic Insomnia Disorder
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2019
Completion date
March 29, 2021
Enrollment
300 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder